Pitt Hyde & Mason Hawkins Buy >50% Stake In GTx Ahead Of Phase II Results
- GTXI has recently seen extraordinary insider buying and outside investment of $38 million.
- Investors Pitt Hyde and Mason Hawkins have a successful track record of identifying undervalued companies poised for growth.
- New investments in GTXI coincide with imminent catalyst of the release of Phase II trial results for metastatic cancer drug, Enobosarm.
- Based on recent, positive Phase II trial results for other cancer drugs in sector, the average near-term gain is 109% post results release.